Search

Your search keyword '"Carrai, Valentina"' showing total 84 results
Start Over Author "Carrai, Valentina"
84 results on '"Carrai, Valentina"'

51. A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria

Author

Mannelli, Francesco, primary, Bencini, Sara, additional, Peruzzi, Benedetta, additional, Cutini, Ilaria, additional, Sanna, Alessandro, additional, Benelli, Matteo, additional, Magi, Alberto, additional, Gianfaldoni, Giacomo, additional, Rotunno, Giada, additional, Carrai, Valentina, additional, Gelli, Anna Maria Grazia, additional, Valle, Veronica, additional, Santini, Valeria, additional, Notaro, Rosario, additional, Luzzatto, Lucio, additional, and Bosi, Alberto, additional

Published
2012
Full Text
View/download PDF

55. A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Author

Passamonti, Francesco, primary, Thiele, Juergen, additional, Barbui, Tiziano, additional, Cazzola, Mario, additional, Ruggeri, Marco, additional, Rodeghiero, Francesco, additional, Randi, Marialuigia, additional, Vannucchi, Alessandro M., additional, Gisslinger, Heinz, additional, Gangat, Naseema, additional, Hanson, Curtis A, additional, Rumi, Elisa, additional, Boveri, Emanuela, additional, Carobbio, Alessandra, additional, Gianatti, Andrea, additional, D'Amore, Emanuele, additional, Bertozzi, Irene, additional, Marino, Filippo, additional, Maffioli, Margherita, additional, Caramazza, Domenica, additional, Antonioli, Elisabetta, additional, Carrai, Valentina, additional, Buxhofer-Ausch, Veronika, additional, Gisslinger, Bettina, additional, Mullauer, Leonhard, additional, Girodon, Francois, additional, Kvasnicka, hans-Michael, additional, Pascutto, Cristiana, additional, and Tefferi, Ayalew, additional

Published
2011
Full Text
View/download PDF

56. Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

Author

Barbui, Tiziano, primary, Thiele, Juergen, additional, Passamonti, Francesco, additional, Rumi, Elisa, additional, Boveri, Emanuela, additional, Ruggeri, Marco, additional, Rodeghiero, Francesco, additional, d'Amore, Emanuele S.G., additional, Randi, Maria Luigia, additional, Bertozzi, Irene, additional, Marino, Filippo, additional, Vannucchi, Alessandro M., additional, Antonioli, Elisabetta, additional, Carrai, Valentina, additional, Gisslinger, Heinz, additional, Buxhofer-Ausch, Veronika, additional, Müllauer, Leonhard, additional, Carobbio, Alessandra, additional, Gianatti, Andrea, additional, Gangat, Naseema, additional, Hanson, Curtis A., additional, and Tefferi, Ayalew, additional

Published
2011
Full Text
View/download PDF

57. Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients

Author

Barbui, Tiziano, primary, Thiele, Juergen, additional, Passamonti, Francesco, additional, Rumi, Elisa, additional, Boveri, Emanuela, additional, Ruggeri, Marco, additional, Rodeghiero, Francesco, additional, D'Amore, Emanuele, additional, Randi, Maria Luigia, additional, Bertozzi, Irene, additional, Marino, Filippo, additional, Vannucchi, Alessandro M., additional, Antonioli, Elisabetta, additional, Carrai, Valentina, additional, Gisslinger, Heinz, additional, Buxhofer-Ausch, Veronika, additional, Müllauer, Leonhard, additional, Carobbio, Alessandra, additional, Gianatti, Andrea, additional, Gangat, Naseema, additional, Hanson, Curtis A., additional, and Tefferi, Ayalew, additional

Published
2010
Full Text
View/download PDF

58. Possible Fruit Protein Effects on Primate Communities in Madagascar and the Neotropics

Author

Ganzhorn, Jörg U., primary, Arrigo-Nelson, Summer, additional, Boinski, Sue, additional, Bollen, An, additional, Carrai, Valentina, additional, Derby, Abigail, additional, Donati, Giuseppe, additional, Koenig, Andreas, additional, Kowalewski, Martin, additional, Lahann, Petra, additional, Norscia, Ivan, additional, Polowinsky, Sandra Y., additional, Schwitzer, Christoph, additional, Stevenson, Pablo R., additional, Talebi, Mauricio G., additional, Tan, Chia, additional, Vogel, Erin R., additional, and Wright, Patricia C., additional

Published
2009
Full Text
View/download PDF

70. A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.

Author

Mannelli, Francesco, Bencini, Sara, Peruzzi, Benedetta, Cutini, Ilaria, Sanna, Alessandro, Benelli, Matteo, Magi, Alberto, Gianfaldoni, Giacomo, Rotunno, Giada, Carrai, Valentina, Gelli, Anna Maria Grazia, Valle, Veronica, Santini, Valeria, Notaro, Rosario, Luzzatto, Lucio, and Bosi, Alberto

Published
2013
Full Text
View/download PDF

71. Patients with ⩾ 20 x 109/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience.

Author

Baldini, Simone, Rigacci, Luigi, Carrai, Valentina, Alterini, Renato, Fjerza, Rajmonda, and Bosi, Alberto

Subjects
BLOOD platelet disorders, THROMBOCYTOPENIA treatment, DRUG dosage, SPLENECTOMY, RETROSPECTIVE studies
Abstract

Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ⩾ 20 × 109/l at baseline could distinguish subjects with such response from those with a delayed one during the early phase of treatment. Our work is a retrospective and single-institution analysis comparing the median platelet count, the median weekly dosage of romiplostim and the median number of weekly platelet counts < 50 × 109/l between patients with a baseline ⩾ 20 × 109/l platelets (n=10, 2 splenectomized) and those with a lower one (n=8, 3 splenectomized) during the first month of treatment with romiplostim. The results show a higher median platelet count (79,5 vs 40,5 × 109/l, p=0,002) and a lower median dose of romiplostim (1 vs 2 mcg/kg/week, p=0,01) in subjects with a baseline ⩾ 20 × 109/l platelets, who also had a trend of less weekly counts < 50 × 109/l platelets (1 vs ee 9 2, p=0,054). These data suggest that patients with ⩾ 20 × 109/l platelets at baseline may achieve a prompt response with the standard dose of romiplostim, but further and larger data are needed in order to assess whether it can be considered in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

73. Characteristics and clinical correlates of MPL515W>L/K mutation in essential thrombocythemia

Author

Vannucchi, Alessandro M., Antonioli, Elisabetta, Guglielmelli, Paola, Pancrazzi, Alessandro, Guerini, Vittoria, Barosi, Giovanni, Ruggeri, Marco, Specchia, Giorgina, Lo-Coco, Francesco, Delaini, Federica, Villani, Laura, Finotto, Silvia, Ammatuna, Emanuele, Alterini, Renato, Carrai, Valentina, Capaccioli, Gloria, Lollo, Simonetta Di, Liso, Vincenzo, Rambaldi, Alessandro, Bosi, Alberto, and Barbui, Tiziano

Abstract

Among 994 patients with essential thrombocythemia (ET) who were genotyped for the MPLW515L/K mutation, 30 patients carrying the mutation were identified (3.0%), 8 of whom also displayed the JAK2V671F mutation. MPLW515L/K patients presented lower hemoglobin levels and higher platelet counts than did wild type (wt) MPL; these differences were highly significant compared with MPLwt/JAK2V617F–positive patients. Reduced hemoglobin and increased platelet levels were preferentially associated with the W515L and W515K alleles, respectively. MPLmutation was a significant risk factor for microvessel disturbances, suggesting platelet hyperreactivity associated with constitutively active MPL; arterial thromboses were increased only in comparison to MPLwt/JAK2wt patients. MPLW515L/K patients presented reduced total and erythroid bone marrow cellularity, whereas the numbers of megakaryocytes, megakaryocytic clusters, and small-sized megakaryocytes were all significantly increased. These data indicate that MPLW515L/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart.

Published
2008
Full Text
View/download PDF

74. Pancreatic iron is a marker of cardiovascular complications in sickle cell disease

Author

Meloni, Antonella, primary, Pistoia, Laura, additional, Missere, Massimiliano, additional, Righi, Riccardo, additional, Vallone, Antonino, additional, Riva, Ada, additional, Positano, Vincenzo, additional, Rigoli, Luciana, additional, Massei, Francesco, additional, Carrai, Valentina, additional, Alberini, Gianna, additional, Cademartiri, Filippo, additional, and Pepe, Alessia, additional

Full Text
View/download PDF

77. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection

Author

Sabrina Quintino, Filomena Longo, Maurizio Miano, Vincenzo Voi, Maria Caterina Putti, Margerita Migone De Amicis, Monica Fortini, Susanna Barella, Barbara Gianesin, Federico Bonetti, Andrea Beccaria, Manuela Balocco, Andrea Piolatto, Saveria Campisi, Rosamaria Rosso, Angelantonio Vitucci, Valentina Carrai, Alessandra Quota, Zelia Borsellino, Antonio Piga, Maddalena Casale, Anna Rita Denotti, Michela Ribersani, Maria Rita Gamberini, Domenico Roberti, Alberto Piperno, Roberto Lisi, Carmelo Fidone, Maria Domenica Cappellini, Sabrina Bagnato, Anna De Giovanni, Micol Quaresima, Valeria Maria, Lorella Pitrolo, Marco Marziali, Giovanna Graziadei, Carmen Gaglioti, Aldo Filosa, Chiara Dal Zotto, Lucia De Franceschi, Irene Motta, Immacolata Tartaglione, Francesco Arcioni, Aurelio Maggio, Marilena Serra, Giovan Battista Ruffo, Massimo Gentile, Elisa De Michele, Anna Spasiano, Paolo Ricchi, Antonella Massa, Silverio Perrotta, R. Mariani, Gian Luca Forni, Longo, Filomena, Gianesin, Barbara, Voi, Vincenzo, Motta, Irene, Pinto, Valeria Maria, Piolatto, Andrea, Spasiano, Anna, Ruffo, Giovan Battista, Gamberini, Maria Rita, Barella, Susanna, Mariani, Raffaella, Fidone, Carmelo, Rosso, Rosamaria, Casale, Maddalena, Roberti, Domenico, Dal Zotto, Chiara, Vitucci, Angelantonio, Bonetti, Federico, Pitrolo, Lorella, Quaresima, Micol, Ribersani, Michela, Quota, Alessandra, Arcioni, Francesco, Campisi, Saveria, Massa, Antonella, De Michele, Elisa, Lisi, Roberto, Miano, Maurizio, Bagnato, Sabrina, Gentile, Massimo, Carrai, Valentina, Putti, Maria Caterina, Serra, Marilena, Gaglioti, Carmen, Migone De Amicis, Margerita, Graziadei, Giovanna, De Giovanni, Anna, Ricchi, Paolo, Balocco, Manuela, Quintino, Sabrina, Borsellino, Zelia, Fortini, Monica, Denotti, Anna Rita, Tartaglione, Immacolata, Beccaria, Andrea, Marziali, Marco, Maggio, Aurelio, Perrotta, Silverio, Piperno, Alberto, Filosa, Aldo, Cappellini, Maria Domenica, De Franceschi, Lucia, Piga, Antonio, and Forni, Gian Luca

Subjects
Sars-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Sars-CoV-2, hemoglobinopathies, Medicine, hemoglobinopathies,SARS-CoV-2 infection, Lethality, Hematology, hemoglobinopathies, business, Virology
Published
2022

78. Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years

Author

Michele Cavo, Francesco Rotondo, Lucia Catani, Marco Ruggeri, Monica Carpenedo, Erminia Baldacci, Silvia Cantoni, Alessandro Lucchesi, Emanuele Sutto, Daniela Bartoletti, Francesca Palandri, Giuseppe Carli, Francesco Rodeghiero, Elena Rossi, Valentina Carrai, Christian Di Pietro, Cristina Santoro, Maria Gabriella Mazzucconi, Wilma Barcellini, Nicola Vianelli, Elena Rivolti, Valerio De Stefano, Giuseppe Auteri, Palandri, Francesca, Santoro, Cristina, Carpenedo, Monica, Cantoni, Silvia, Barcellini, Wilma, Carli, Giuseppe, Carrai, Valentina, Rossi, Elena, Rivolti, Elena, Lucchesi, Alessandro, Rotondo, Francesco, Baldacci, Erminia, Auteri, Giuseppe, Sutto, Emanuele, Di Pietro, Christian, Catani, Lucia, Bartoletti, Daniela, De Stefano, Valerio, Ruggeri, Marco, Mazzucconi, Maria Gabriella, Cavo, Michele, Rodeghiero, Francesco, and Vianelli, Nicola

Subjects
medicine.medical_specialty, Eltrombopag, Azathioprine, 030204 cardiovascular system & hematology, 03 medical and health sciences, chemistry.chemical_compound, Elderly, 0302 clinical medicine, Prednisone, Internal medicine, medicine, Humans, Dexamethasone, Aged, Purpura, Thrombocytopenic, Idiopathic, Romiplostim, Toxicity, business.industry, Retrospective cohort study, Hematology, medicine.disease, Comorbidity, Thrombocytopenia, Immune thrombocytopenia, Settore MED/15 - MALATTIE DEL SANGUE, ITP, TPO-receptor agonists, chemistry, TPO-receptor agonist, 030220 oncology & carcinogenesis, Splenectomy, Rituximab, business, Immunosuppressive Agents, medicine.drug
Abstract

INTRODUCTION: Primary Immune thrombocytopenia (ITP) in the elderly is a major clinical challenge which is increasingly frequent due to global ageing population. MATERIALS AND METHODS: To describe baseline ITP features, management, and outcome, a centralized electronic database was established, including data of 451 patients aged ≥60years that were treated from 2000 onwards and were observed for ≥1year (total observation of 2704 patient-years). RESULTS: At ITP diagnosis, median age was 71.1years (age≥75: 42.8%); 237 (53.9%) patients presented with haemorrhages (grade≥3: 7.5%). First-line therapy included prednisone (82.9%), dexamethasone (14.6%), thrombopoietin-receptor agonists (TRAs, 1.3%), and oral immunosuppressive agents (1.1%). Prednisone starting dose ≥1mg/kg/d (p=.01) and dexamethasone 40mg/d (p&nbsp

Published
2019

79. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers

Author

Angela Maria Ciminello, Giorgina Specchia, Fabrizio Pane, Silvia Cantoni, Roberto Cairoli, Felicetto Ferrara, Erminia Baldacci, Francesco Zaja, Ugo Consoli, Alessandra Ricco, Andrea Artoni, Monica Carpenedo, Valerio De Stefano, Michele Nichelatti, Mariella D'Adda, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Wilma Barcellini, Valentina Carrai, Andrea Visentin, Maria Gabriella Mazzucconi, Marco Ruggeri, Domenica Caramazza, Cantoni, Silvia, Carpenedo, Monica, Mazzucconi, Maria Gabriella, DE STEFANO, Valerio Flavio, Carrai, Valentina, Ruggeri, Marco, Specchia, Giorgina, Vianelli, Nicola, Pane, Fabrizio, Consoli, Ugo, Artoni, Andrea, Zaja, Francesco, D'Adda, Mariella, Visentin, Andrea, Ferrara, Felicetto, Barcellini, Wilma, Caramazza, Domenica, Baldacci, Erminia, Rossi, Elena, Ricco, Alessandra, Ciminello, Angela, Rodeghiero, Francesco, Nichelatti, Michele, Cairoli, Roberto, Cantoni, S, Carpenedo, M, Mazzucconi, M, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Artoni, A, Zaja, F, D'Adda, M, Visentin, A, Ferrara, F, Barcellini, W, Caramazza, D, Baldacci, E, Rossi, E, Ricco, A, Ciminello, A, Rodeghiero, F, Nichelatti, M, Cairoli, R, and De Stefano, Valerio

Subjects
Adolescent, Adult, Aged, 80 and over, Female, Humans, Italy, Male, Middle Aged, Purpura, Thrombocytopenic, Idiopathic, Receptors, Thrombopoietin, Retrospective Studies, Surveys and Questionnaires, Young Adult, Hematology, Aged, 80 and over, Purpura, Thrombocytopenic, Idiopathic, Receptors, Thrombopoietin, Thrombopoietin receptor agonists, chemistry.chemical_compound, 0302 clinical medicine, Retrospective Studie, Surveys and Questionnaire, Young adult, Thrombopoietin receptor agonists, Immune thrombocytopenia, immune thrombocytopenia, 030220 oncology & carcinogenesis, Receptor, medicine.drug, Human, medicine.medical_specialty, Thrombopoietin Receptor Agonists, Eltrombopag, 03 medical and health sciences, Internal medicine, medicine, Adverse effect, Romiplostim, business.industry, Retrospective cohort study, Immune thrombocytopenia, Settore MED/15 - MALATTIE DEL SANGUE, chemistry, Immunology, ITP, business, 030215 immunology
Abstract

Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.

Published
2018

80. Corrigendum to 'Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia' [Int. Immunopharmacol. 44 (2017) 38-42]

Author

Antonio Pecoraro, Liliana Nappi, Serena Bongiovanni, Giuseppe Spadaro, Elisabet Speckman, Jan Janssen, Donatella Lamacchia, Alberto Bosi, Valentina Carrai, Cinzia Milito, Francesca Bacchiarri, Andrea Ferraro, Dietmar Reichert, Isabella Quinti, Andrea Matucci, Chiara Guarnieri, Azra Hibbeler, Alessandra Vultaggio, Spadaro, Giuseppe, Vultaggio, Alessandra, Bosi, Alberto, Reichert, Dietmar, Janssen, Jan, Lamacchia, Donatella, Nappi, Liliana, Pecoraro, Antonio, Milito, Cinzia, Ferraro, Andrea, Matucci, Andrea, Bacchiarri, Francesca, Carrai, Valentina, Hibbeler, Azra, Speckman, Elisabet, Guarnieri, Chiara, Bongiovanni, Serena, and Quinti, Isabella

Subjects
Pharmacology, business.industry, INT, Immunology, Human Normal Immunoglobulin, Medicine, Immunology and Allergy, business, Immune thrombocytopenia
Published
2017

81. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

Author

Chiara Guarnieri, Jan Janssen, Isabella Quinti, Cinzia Milito, Alberto Bosi, Andrea Matucci, Donatella Lamacchia, Andrea Ferraro, Liliana Nappi, Serena Bongiovanni, Francesca Bacchiarri, Antonio Pecoraro, Giuseppe Spadaro, Valentina Carrai, Elisabet Speckman, Dietmar Reichert, Alessandra Vultaggio, Azra Hibbeler, Spadaro, Giuseppe, Vultaggio, Alessandra, Alberto Bosi, A., Reichert, Dietmar, Janssen, Jan, Lamacchia, Donatella, Nappi, Liliana, Pecoraro, Antonio, Milito, Cinzia, Ferraro, Andrea, Matucci, Andrea, Bacchiarri, Francesca, Carrai, Valentina, Hibbeler, Azra, Speckman, Elisabet, Guarnieri, Chiara, Bongiovanni, Serena, and Quinti, Isabella

Subjects
0301 basic medicine, Tachycardia, Male, Pediatrics, Cost effectiveness, Intravenous immunoglobulin, Quality of life, Rapid infusion, Adolescent, Adult, Female, Humans, Immunoglobulins, Intravenous, Immunologic Deficiency Syndromes, Immunotherapy, Middle Aged, Patient Compliance, Prospective Studies, Purpura, Thrombocytopenic, Idiopathic, Quality of Life, Treatment Outcome, Young Adult, Immunology and Allergy, Immunology, Pharmacology, 0302 clinical medicine, hemic and lymphatic diseases, Cost effectivene, Young adult, Prospective cohort study, Immunologic Deficiency Syndrome, Idiopathic, Tolerability, medicine.symptom, Intravenous, Human, medicine.medical_specialty, Vital signs, Immunoglobulins, 03 medical and health sciences, medicine, Adverse effect, Purpura, business.industry, Thrombocytopenic, Prospective Studie, 030104 developmental biology, Blood pressure, Immunoglobulins, Intravenou, business, 030215 immunology
Abstract

Intravenous immunoglobulin (IVIg) is accepted as an effective and well-tolerated treatment for primary and secondary immunodeficiencies (ID) and immune thrombocytopenia (ITP). Adverse reactions of IVIg are usually mild, comprising transient flu-like symptoms, change in blood pressure and tachycardia. However IVIg therapy can be burdensome for both patients and healthcare facilities, since the infusion may take up to 4 h to administer. The objective of our multicentre, prospective, open-label phase III trial was to evaluate the tolerability and safety of human normal immunoglobulin 50 g/l (Ig VENA) at high intravenous infusion rates in adult patients with ID and ITP who had previously tolerated IVIg treatment, by progressively increasing infusion rate up to 8 ml/kg/hr. 39 ID patients received three infusions, 5 ITP patients received up to a maximum of 5 infusions for a maximum of 5 days. Overall 55 adverse events were reported in 18 patients, and all were mild and self-limiting. Two serious adverse events occurred in ID patients and 1 in an ITP patient; none was fatal or treatment-related. No clinically significant changes or abnormalities were observed in vital signs, laboratory results and HRQoL. In summary, in this study, more rapid IVIg infusions were well tolerated by ID and ITP patients, while maintaining their quality of life, helping to minimise the time spent in outpatient hospital visiting to potentially optimise adherence to treatment.

Published
2016

82. Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.

Author

Longo F, Gianesin B, Voi V, Motta I, Pinto VM, Piolatto A, Spasiano A, Ruffo GB, Gamberini MR, Barella S, Mariani R, Fidone C, Rosso R, Casale M, Roberti D, Dal Zotto C, Vitucci A, Bonetti F, Pitrolo L, Quaresima M, Ribersani M, Quota A, Arcioni F, Campisi S, Massa A, De Michele E, Lisi R, Miano M, Bagnato S, Gentile M, Carrai V, Putti MC, Serra M, Gaglioti C, Migone De Amicis M, Graziadei G, De Giovanni A, Ricchi P, Balocco M, Quintino S, Borsellino Z, Fortini M, Denotti AR, Tartaglione I, Beccaria A, Marziali M, Maggio A, Perrotta S, Piperno A, Filosa A, Cappellini MD, De Franceschi L, Piga A, and Forni GL

Subjects
Adult, Age Factors, Aged, Aged, 80 and over, COVID-19 epidemiology, COVID-19 mortality, Female, Hemoglobinopathies epidemiology, Hemoglobinopathies mortality, Humans, Italy epidemiology, Male, Middle Aged, Prevalence, Risk Factors, SARS-CoV-2 isolation & purification, Thalassemia complications, Thalassemia epidemiology, Thalassemia mortality, Young Adult, COVID-19 complications, Hemoglobinopathies complications
Published
2022
Full Text
View/download PDF

83. Patients with ≥ 20 × 10(9)/l platelets at baseline may have a prompt response to romiplostim during the early phase of treatment: an italian single-institution experience.

Author

Baldini S, Rigacci L, Carrai V, Alterini R, Fjerza R, and Bosi A

Abstract

Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 × 10(9)/l at baseline could distinguish subjects with such response from those with a delayed one during the early phase of treatment. Our work is a retrospective and single-institution analysis comparing the median platelet count, the median weekly dosage of romiplostim and the median number of weekly platelet counts < 50 × 10(9)/l between patients with a baseline ≥ 20 × 10(9)/l platelets (n=10, 2 splenectomized) and those with a lower one (n=8, 3 splenectomized) during the first month of treatment with romiplostim. The results show a higher median platelet count (79,5 vs 40,5 × 10(9)/l, p=0,002) and a lower median dose of romiplostim (1 vs 2 mcg/kg/week, p=0,01) in subjects with a baseline ≥ 20 × 10(9)/l platelets, who also had a trend of less weekly counts < 50 × 10(9)/l platelets (1 vs 2, p=0,054). These data suggest that patients with ≥ 20 × 10(9)/l platelets at baseline may achieve a prompt response with the standard dose of romiplostim, but further and larger data are needed in order to assess whether it can be considered in clinical practice.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results